Quick Answer
Estrella Immunopharma, Inc. reported Stockholders Equity of -$10.37 million for fiscal year 2025.
Estrella Immunopharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$10.37M | -7312.1% |
| 2024 | $143.7K | -96.6% |
| 2024 | $4.27M | +136.4% |
| 2023 | -$11.74M | -420.6% |
| 2022 | -$2.26M | -116.9% |
| 2022 | -$1.04M | -3.3% |
| 2021 | -$1.01M | — |
| 2020 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$9.84M | -1418.1% | -61.4% |
| June 30, 2025 | -$6.09M | -242.6% | -232.9% |
| March 31, 2025 | -$1.83M | -121.6% | -1373.9% |
| December 31, 2024 | $143.7K | -98.4% | -80.7% |
| September 30, 2024 | $746.3K | -92.6% | -82.5% |
| June 30, 2024 | $4.27M | +136.4% | -49.7% |
| March 31, 2024 | $8.49M | +193.2% | -6.1% |
| December 31, 2023 | $9.05M | +239.7% | -10.1% |
- Estrella Immunopharma, Inc. showed a decrease of -7312.1% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: